277.22
Penumbra Inc stock is traded at $277.22, with a volume of 728.38K.
It is up +2.43% in the last 24 hours and down -1.13% over the past month.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
See More
Previous Close:
$270.64
Open:
$274
24h Volume:
728.38K
Relative Volume:
1.59
Market Cap:
$10.53B
Revenue:
$1.16B
Net Income/Loss:
$34.55M
P/E Ratio:
322.35
EPS:
0.86
Net Cash Flow:
$134.18M
1W Performance:
+1.82%
1M Performance:
-1.13%
6M Performance:
+34.82%
1Y Performance:
+36.56%
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
PEN
Penumbra Inc
|
277.22 | 10.53B | 1.16B | 34.55M | 134.18M | 0.86 |
![]()
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-14-25 | Initiated | BofA Securities | Buy |
Jan-21-25 | Initiated | UBS | Buy |
Dec-17-24 | Initiated | Oppenheimer | Outperform |
Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Sep-18-24 | Initiated | Stifel | Buy |
Sep-03-24 | Initiated | Leerink Partners | Outperform |
Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
Jul-19-23 | Initiated | Robert W. Baird | Outperform |
Mar-29-23 | Downgrade | Needham | Buy → Hold |
Jan-30-23 | Initiated | Piper Sandler | Overweight |
Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
Oct-12-22 | Initiated | Jefferies | Buy |
Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
Sep-09-22 | Upgrade | Needham | Hold → Buy |
Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
Apr-19-22 | Initiated | Deutsche Bank | Buy |
Mar-08-22 | Initiated | Needham | Hold |
Sep-16-21 | Initiated | Truist | Buy |
Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
Oct-07-20 | Resumed | Canaccord Genuity | Buy |
Sep-29-20 | Initiated | BTIG Research | Buy |
Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
Mar-05-20 | Initiated | Citigroup | Buy |
Jun-13-19 | Reiterated | BofA/Merrill | Buy |
May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
May-21-19 | Initiated | William Blair | Outperform |
Oct-29-18 | Resumed | BofA/Merrill | Buy |
Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
Feb-21-18 | Initiated | William Blair | Outperform |
Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
What To Expect From Penumbra’s (PEN) Q1 Earnings - Yahoo Finance
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation - GlobeNewswire
Why Penumbra (PEN) is Poised to Beat Earnings Estimates Again - Yahoo Finance
Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits (PR Newswire) - Aktiellt
Penumbra CEO Adam Elsesser sells $4.54 million in stock By Investing.com - Investing.com South Africa
Penumbra CEO Adam Elsesser sells $4.54 million in stock - Investing.com
Penumbra director O’Rourke sells shares worth $13,560 By Investing.com - Investing.com South Africa
Penumbra director O’Rourke sells shares worth $13,560 - Investing.com
Investors more bullish on Penumbra (NYSE:PEN) this week as stock lifts 6.4%, despite earnings trending downwards over past five years - simplywall.st
Penumbra (PEN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
RBC Lifts Price Target on Penumbra to $315 From $313, Keeps Outperform Rating - marketscreener.com
BTIG Adjusts Penumbra (PEN) Price Target as MedTech Q1 Results L - GuruFocus
Micro Guide Catheters Market to Witness Remarkable Growth with - openPR.com
Truist Adjusts Price Target for Penumbra (PEN) Amid Market Volat - GuruFocus
Truist Cuts Price Target on Penumbra to $315 From $325, Keeps Buy Rating - MarketScreener
Penumbra price target lowered to $315 from $325 at Truist - TipRanks
Is Penumbra Gaining or Losing Market Support? - Benzinga
3 Reasons PEN is Risky and 1 Stock to Buy Instead - The Globe and Mail
PEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Penumbra, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm - marketscreener.com
Reasons to Retain Penumbra Stock in Your Portfolio for Now - MSN
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Penumbra, Inc. (NYSE: PEN) - PR Newswire
(PEN) Trading Report - news.stocktradersdaily.com
Penumbra Inc director Wilder Thomas sells $96,094 in stock By Investing.com - Investing.com India
Penumbra CEO Adam Elsesser sells $4.5 million in stock By Investing.com - Investing.com South Africa
Penumbra CEO Adam Elsesser sells $4.5 million in stock - Investing.com
Penumbra Inc director Wilder Thomas sells $96,094 in stock - Investing.com
Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025 - BioSpace
Penumbra Q1 2025 Earnings Date Confirmed: Key Details for Investors - Stock Titan
Penumbra EVP Johanna Roberts sells $161,466 in stock By Investing.com - Investing.com Australia
Penumbra director Harpreet Grewal sells $53,434 in stock By Investing.com - Investing.com Canada
Penumbra director Wilder Thomas sells $95,248 in common stock - Investing.com
Penumbra director Harpreet Grewal sells $53,434 in stock - Investing.com
Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vac - GuruFocus
Breakthrough Clinical Data: Penumbra's CAVT Slashes Hospital Stays by 46%, Achieves 99% Success Rate - Stock Titan
Meiji Yasuda Asset Management Co Ltd. Buys New Position in Penumbra, Inc. (NYSE:PEN) - MarketBeat
ROSEN, A LEADING LAW FIRM, Encourages Penumbra, Inc. Investors to Secure Counsel Before Important March 16 DeadlinePEN - PR Newswire
Penumbra Insider Sold Shares Worth $3,405,253, According to a Recent SEC Filing - MarketScreener
Penumbra director Arani sells $3.41 million in stock - Investing.com India
Thrombectomy Devices Market Surge: Key Players & Future Outlook - openPR.com
New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues - MSN
Imperative Care Expands Precision Thrombectomy Portfolio - Diagnostic and Interventional Cardiology
Penumbra CEO Adam Elsesser sells $4.59 million in stock By Investing.com - Investing.com Australia
Penumbra CEO Adam Elsesser sells $4.59 million in stock - Investing.com
Do Its Financials Have Any Role To Play In Driving Penumbra, Inc.'s (NYSE:PEN) Stock Up Recently? - Yahoo Finance
Has Penumbra, Inc.'s (NYSE:PEN) Impressive Stock Performance Got Anything to Do With Its Fundamentals? - simplywall.st
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):